ALXO stock icon

ALX Oncology
ALXO

$6.73
8.94%

Market Cap: 351M

 

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 74

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

295% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $400K

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

14% more funds holding

Funds holding: 93 [Q4 2023] → 106 (+13) [Q1 2024]

0.56% less ownership

Funds ownership: 91.86% [Q4 2023] → 91.3% (-0.56%) [Q1 2024]

10% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 31

25% less capital invested

Capital invested by funds: $681M [Q4 2023] → $510M (-$171M) [Q1 2024]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 2 (-1) [Q1 2024]

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$14
108%
upside
Avg. target
$20
197%
upside
High target
$25
271%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
271%upside
$25
Buy
Reiterated
10 Jun 2024
HC Wainwright & Co.
Swayampakula Ramakanth
197%upside
$20
Buy
Reiterated
10 Apr 2024
HC Wainwright & Co.
Swayampakula Ramakanth
197%upside
$20
Buy
Maintained
11 Mar 2024
Piper Sandler
Christopher Raymond
212%upside
$21
Overweight
Maintained
8 Mar 2024
Stifel
Bradley Canino
108%upside
$14
Hold
Downgraded
8 Mar 2024

Financial journalist opinion